Tango Therapeutics, Inc. (TNGX) Tops Q2 EPS by 10c

Tango Therapeutics, Inc. (NASDAQ: TNGX) reported Q2 EPS of ($0.23), $0.10 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $14.6 million versus the consensus estimate of $7.19 million.

For earnings history and earnings-related data on Tango Therapeutics, Inc. (TNGX) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• UBS Reiterates Neutral Rating on Intuit (INTU), Says Investor Day Not 'Sentiment-Changing'
• Element Solutions (ESI) PT Lowered to $47 at UBS, Buy Rating Maintained